Skip to main navigation

>> Site Menu

Our Company
Our Science
Our Products
Join Us
INVESTORS & MEDIA

Kodiak Sciences

>> Site Menu

Our Company
Our Science
Our Products
Join Us
INVESTORS & MEDIA

News Releases

> News - Sub Nav

Press Releases

News Releases

December 3, 2019

Kodiak Sciences Announces Pricing of $276.0 Million Public Offering of Common Stock

Additional Formats

PDF Version

December 2, 2019

Kodiak Sciences Announces Proposed Offering of Common Stock

Additional Formats

PDF Version

December 2, 2019

Kodiak Sciences to Present at the Evercore ISI HealthCONx Conference

Additional Formats

PDF Version

December 2, 2019

Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors

Additional Formats

PDF Version

November 12, 2019

Kodiak Sciences Announces Third Quarter 2019 Financial Results and Recent Business Highlights

Additional Formats

PDF Version

November 8, 2019

Kodiak Sciences to Report Third Quarter 2019 Results and Host Business Highlights Webcast on November 12, 2019

Additional Formats

PDF Version

October 11, 2019

Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day

Additional Formats

PDF Version

October 11, 2019

Kodiak Sciences to Host R&D Day on October 14 in San Francisco to Highlight Recent Clinical Progress and Development Planning for KSI-301

Additional Formats

PDF Version

October 10, 2019

Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration

Additional Formats

PDF Version

October 7, 2019

Kodiak Sciences Announces Upcoming Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting

Additional Formats

PDF Version

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Page 5
Current page 6
Page 7
Page 8
Page 9
Next page
Last page

Displaying 51 - 60 of 88

Disclaimer

Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.

KODIAK SCIENCES INC.

1200 Page Mill Road
Palo Alto, CA 94304
United States of America

Kodiak Sciences GMBH
Dammstrasse 19
6300 ZUG
Switzerland

info@kodiak.com

Kodiak Sciences Valais GMBH
Rottenstrasse 5
3930 VISP
Switzerland

LinkedIn Twitter

Copyright © 2022 Kodiak Sciences Inc.